DE19523660A1 - Antigens with characteristics of retro-virus - Google Patents

Antigens with characteristics of retro-virus

Info

Publication number
DE19523660A1
DE19523660A1 DE1995123660 DE19523660A DE19523660A1 DE 19523660 A1 DE19523660 A1 DE 19523660A1 DE 1995123660 DE1995123660 DE 1995123660 DE 19523660 A DE19523660 A DE 19523660A DE 19523660 A1 DE19523660 A1 DE 19523660A1
Authority
DE
Germany
Prior art keywords
virus
antigens
paga
retro
immune
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE1995123660
Other languages
German (de)
Inventor
Erwin Goetsch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to DE1995123660 priority Critical patent/DE19523660A1/en
Publication of DE19523660A1 publication Critical patent/DE19523660A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/12Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241Nucleotidyltransferases (2.7.7)
    • C12N9/1247DNA-directed RNA polymerase (2.7.7.6)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Antigens are claimed that are adapted to retroviruses and possess adequate characteristics of the virus. The PagA antigens exchange with the virus with the help of the protein biosynthesis genetic material, and destroy the virus with the restriction.

Description

Die Immunschwäche Aids ist durch ausgeprächte Immun­ suppression gekennzeichnet, die klinisch mit opportunis­ tischen Infektionen, Degenerationen im Zentralnervensys­ tem und malignen Tumoren einhergeht. Das Krankheitsbild wird durch ein Virus (Retrovirade) verursacht, daß Tumor­ zellen und Makrophagen befällt. Die beim Menschen be­ kannten HIV-Typen unterscheiden sich im Genom und in der Antigenizität, lösen aber klinisch gleiche Krankheits­ bilder aus.The immune deficiency AIDS is due to pronounced immune suppression characterized clinically with opportunis infections, degenerations in the central nervous system and malignant tumors. The clinical picture is caused by a virus (retrovirade) that tumor cells and macrophages. The human be Known HIV types differ in genome and in Antigenicity, but solve clinically the same disease pictures from.

Das Genom besteht aus 2 identischen RNS-Strängen. Es ist zusammen mit den beiden Enzymen "Reverse Transkriptase" und der "Interase" von einem sog. Kapsid umgeben. Dieses Kapsid ist in von der Wirtszelle stammende Phospholipidmembran eingepackt. In dieser Hülle ist jenes genetische Material integriert, daß den Ablauf der HIV-Infektion bestimmt!
In einem ersten Schritt kommt es zu einer hochaffinen Bindung an CD4-Moleküle, die von T-Zellen und Makrophagen exprimiert werden, worauf es zur Infektion dieser Zellen führt. Nach dem Eindringen des Virus werden die Enzyme des Nukleoproteinkomplexes aktiv, wonach die Reproduktion des Virus einsetzt.
The genome consists of 2 identical RNA strands. Together with the two enzymes "reverse transcriptase" and the "interase" it is surrounded by a so-called capsid. This capsid is packaged in phospholipid membrane derived from the host cell. The genetic material that determines the course of HIV infection is integrated in this shell!
The first step is high-affinity binding to CD4 molecules that are expressed by T cells and macrophages, which leads to infection of these cells. After the virus penetrates, the enzymes of the nucleoprotein complex become active, after which the reproduction of the virus begins.

Das Hauptproblem liegt daran, daß die HIV-Infek­ tion die komplexen Wechselbeziehungen zwischen den Effekten des Virus auf die Funktion den immunkomponennten Zellen und der Immunantwort des Wirts auf das Virus widerspiegelt, und mit indirekten Mechanismen die noch nicht infizierten Zellen des Immunsystems außer Betrieb setzt. Da das Virus von Zelle zu Zelle überspringen kann können sich Antikörper, die nicht auswechselbaren Abschnitte des Virus erkennen, die Fusion bloc­ kieren und freie Viruspartikel neutralisieren, als nützlich erweisen.The main problem is that the HIV infection tion the complex interrelations between the effects of the virus on the function immune component cells and the immune response of the host reflects on the virus, and with indirect mechanisms that are not yet infected Immune cells of the immune system. Because the virus can jump from cell to cell can become antibodies that are not interchangeable Detect sections of the virus that merge bloc and neutralize free virus particles, prove useful.

Stand der TechnikState of the art

Die Prozesse zur Nachlassung der Aktivität von Symptomen die mit dem HIV assoziieren, zeigten keinen Erfolg. (Klasse A 61 K, Gruppe 39/00, Intern. Kl - Nr. WO 89/02749). Auch andere Vakzine und Therapien gaben keine Lösungen. (Aids vom Molekül zur Pandemie, von Michael C. Koch 1989 Heidelberg Spektrum des Wissens-Verlag Ges. 1989 ISBN 3-922508-9).The processes to decrease the activity of Symptoms associated with HIV showed no success. (Class A 61 K, group 39/00, Intern. Kl No. WO 89/02749). There were also no other vaccines and therapies Solutions. (AIDS from molecule to pandemic, by Michael C. Koch 1989 Heidelberg Spectrum of Wissens-Verlag Ges. 1989 ISBN 3-922508-9).

Lösung des Problemsthe solution of the problem

Das HIV besitzt eine Schwachstelle! Diese ist in der Genetik zu finden. Damit sich das Virus trans­ kriptieren und vermehren kann, muß es das Phospho­ lipidmembran verlassen und das Kapsid öffnen. Danach wird es lysiert.HIV has a weak point! This is in to find genetics. So that the virus trans script and multiply, it must be the phospho Leave the lipid membrane and open the capsid. Then it is lysed.

Dieses "Lysieren" ist sein Schwachpunkt, wo PagA sich einsetzt! This "lysing" is its weak point where PagA is committed!  

Das PagA wirkt gegenüber dem Immunsystem anti­ thetisch. Ferner besitzt es adequante Charakteren mit dem Virus. So paßt sich PagA dem Virus an und geht in einer hochaffinen Bindung mit das Virus einher. Dabei wird das Enzym "Reverse Transkriptase" gegen den Nukleinsäurepolymorphismus von PagA umgetauscht. Somit wird die virale DNS wieder in RNS übersetzt. Das Virus wird wieder lysiert. Nun wird mit der Proteinbiosynthese des PagA der genetische Cod des Virus verändert, wobei die Translation des PagA behilflich ist.The PagA has an anti-immune effect thetic. It also has adequate characters with the virus. So PagA adapts to the virus and goes in a high affinity bond with the virus hand in hand. The enzyme "reverse transcriptase" against the nucleic acid polymorphism of PagA exchanged. Thus the viral DNA is again in RNA translated. The virus is lysed again. Well now with the protein biosynthesis of PagA the genetic Cod of the virus changed, the translation of the PagA is helpful.

Das Virus ist nun völlig zerstört!
Die Zellhybride aus der Fl-Generation (PagA+HIV) werden zusammen mit den freigesetzten Viruspar­ tikel völlig entfernt.
The virus is now completely destroyed!
The cell hybrids from the Fl generation (PagA + HIV) are completely removed together with the released virus particles.

PagA kann nicht bei einem intakten Immunsystem ein­ gesetzt werden, da es durch Antikörper (meist IgM) zerstört wird. Bei Krebsbehandlungen empfiehlt sich die Impfung direkt in der Metastase.PagA cannot respond to an intact immune system as it is caused by antibodies (mostly IgM) gets destroyed. Cancer treatments are recommended vaccination directly in the metastasis.

Bereits 1982 hatte ich damit Erfolg. Bei stationärer Behandlung meiner Appendizitis (Blinddarm war 12 Std. vor Krankenhauseinlieferung durchgebrochen) fanden die Ärzte 2 Narben im Magen. Hierbei wurde der Verdacht auf Krebs gesetzt. Die Heilung ist den Ärzten unklar. Antikörper wurden nicht festgestellt. Somit verdanke ich PagA mein Leben!I had success with this back in 1982. With inpatient treatment of my appendicitis (Appendix was 12 hours before hospital admission the doctors found 2 scars in the stomach. Here, suspicion of cancer was raised. The Healing is unclear to the doctors. Antibodies were not found. So I owe PagA mine Life!

Claims (1)

Antigene, die sich den Retroviren anpassen und ade­ quante Charakterien mit den Viren besitzen, dadurch gekennzeichnet, das die PagA - Antigene mit Hilfe der Proteinbiosynthese genetisches Material des Virus austauscht, und das Virus mit der Restriktion völlig zerstört.Antigens that adapt to the retroviruses and have adequate quantum characters with the viruses, characterized in that the PagA antigens exchange genetic material of the virus with the help of protein biosynthesis, and completely destroy the virus with the restriction.
DE1995123660 1995-06-29 1995-06-29 Antigens with characteristics of retro-virus Withdrawn DE19523660A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE1995123660 DE19523660A1 (en) 1995-06-29 1995-06-29 Antigens with characteristics of retro-virus

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE1995123660 DE19523660A1 (en) 1995-06-29 1995-06-29 Antigens with characteristics of retro-virus

Publications (1)

Publication Number Publication Date
DE19523660A1 true DE19523660A1 (en) 1997-01-02

Family

ID=7765557

Family Applications (1)

Application Number Title Priority Date Filing Date
DE1995123660 Withdrawn DE19523660A1 (en) 1995-06-29 1995-06-29 Antigens with characteristics of retro-virus

Country Status (1)

Country Link
DE (1) DE19523660A1 (en)

Similar Documents

Publication Publication Date Title
DE69027187T2 (en) METHOD FOR INACTIVATING VIRUSES IN VIRUS POLLUTED PHARMACEUTICAL COMPOSITIONS
DE69632395T2 (en) COCHLEATE DELIVERY VALVE FOR BIOLOGICALLY RELEVANT MOLECULES
DE69519670T2 (en) MICROPARTICLE WITH DELIVERY SYSTEM
EP3413907B1 (en) Blood treatment with inactivation of circulating nucleic acids
JP6109881B2 (en) Method for reducing the viral and microbial content of a solid-containing biological extract
DE69936337T2 (en) METHOD FOR DEVELOPING AN HIV VACCINE
CN101790377A (en) Prophylactic or alleviating agent for peripheral nerve disorder induced by anti-cancer agent
DE60315636T2 (en) BACTERIOPHAGES SUITABLE FOR THE THERAPY AND PROPHYLAXIS OF BACTERIAL INFECTIONS
DE3019847C2 (en) Process for the production of human interferon
DE68909100T2 (en) Physiologically active substances, processes for their preparation and pharmaceutical compositions thereof.
AU7143196A (en) Therapeutic applications of animal sera including horse serum in the treatment of aids, cancer, and other viral and bacterial diseases
DE69434961D1 (en) FUNCTION AND ACTIVITY OF THE VIRAL PROTEIN R (VPR)
JPH11199495A (en) Antiallergic agent using enteric capsule
JPH0539305A (en) Immuno suppressive polysaccharide extracted from astragalus membranaceous and pharma- ceutical composition containing same
DE19523660A1 (en) Antigens with characteristics of retro-virus
Frejborg et al. Current landscape in antiviral drug development against herpes simplex virus infections
DE69837923T2 (en) COMPONENT OF BROMELAIN
JPH01120284A (en) Incomplete particle of hiv and production thereof
JPS63309200A (en) Measurement of hiv
US5603963A (en) Method for the treatment of retroviral diseases such as acquired immune deficiency syndrome utilizing (pseudo)halogen complexes of gold(1)
AT405608B (en) METHOD FOR INACTIVATING PATHOGENS, ESPECIALLY VIRUSES, IN A BIOLOGICAL MATERIAL
DE60118175T2 (en) METHOD FOR THE PRODUCTION OF AN IMMUNOTROPIC ANTIVIRAL COMPOSITION
UA78673C2 (en) Use of lactobacillus strains for treating prostate inflammation and benign prostate hyperplasias
Panno Gene therapy: treating disease by repairing genes
Emengaha et al. Gene therapy in the developing countries

Legal Events

Date Code Title Description
8122 Nonbinding interest in granting licenses declared
8133 Disposal/non-payment of the application fee